ClinicalTrials.gg
RecruitingNCT06683001Updated Apr 13, 2026

National Heart Failure Registry

An observational study in Chronic Heart Failure, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
20,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Heart Failure with a site in Russia — 9 open to participants now, 10 under way, none of them phase 3. Heart Failure · Russia.

Planned enrollment
2nd of 10
20,000 · median 250
Started
2024
the only one that year
Observational
10 of 25
6 open now
Registered
19th of 25
by date
Lead sponsor
3 of 25
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Among the 25 studies in Heart Failure with a site in Russia, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2024, is one of 10 observational ones, and was the 19th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 25 studies in Heart Failure with a site in Russia are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Heart Failure with a site in Russia, or all of them as a file.
02

Study summary

A prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the Russian Federation.

The study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the method of surgical intervention) and examination.

A control observation group is not intended.

Read the detailed description

The study will include retrospective and prospective data of patients with an outpatient or inpatient diagnosis of CHF.

The duration of the observation period of an individual patient with CHF is limited by the study period, or the patient's death, and includes the studied retrospective and dynamic prospective parameters. Prospective data of CHF (any stage and FC) subjects are planned to be included sequentially as they appear in inpatient CHF centers and outpatient CHF offices until 12/31/2027 inclusive and further upon extension of the study.

Retrospective data will be provided by chief freelance cardiologists of 33 constituent entities of the Russian Federation (Central Federal District, Ural Federal District, Siberian Federal District, Far Eastern Federal District) (individually, according to agreement)

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

At least 3% of CHF subjects in the target regions of Russia will be included in that trial by performing thier medical records analysis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any stage and/or any class of CHF

Exclusion criteria

Exclusion Criteria:

  • Subjects whose source records cant be obtained for the analysis
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
20,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Age of subjects with different phenotypes and stages of CHF

    Time frame: Every 12 months, up to 3 years

  2. Female to male sex ratio of subjects with different phenotypes and stages of CHF

    Time frame: Every 12 months, up to 3 years

  3. Clinical status of subjects with different phenotypes and stages of CHF

    Time frame: Every 12 months, up to 3 years

  4. Proportion of employable and working subjects with different phenotypes and stages of CHF

    Time frame: Every 12 months, up to 3 years

  5. The proportion of subjects with different algorithms for diagnosing CHF and the proportion of subjects with a verified diagnosis of CHF (established according to the recommended algorithm for diagnosing CHF)

    Time frame: Every 12 months, up to 3 years

  6. The proportion of subjects taking drugs of each class and all four classes of the recommended four-component therapy regimen (in the overall choice and in different phenotypes of CHF; working/non-working age; working/non-working)

    Time frame: Every 12 months, up to 3 years

  7. Number and proportion of subjects with wearable devices when using an online tool for identifying subjects with CHF with indications for high-tech medical care

    Time frame: Every 12 months, up to 3 years

  8. Number and proportion of subjects when using an online tool for identifying subjects with CHF with indications for high-tech medical care

    Time frame: Every 12 months, up to 3 years

Secondary outcomes

  1. Proportions of subjects with an increase in EF ≥10% and a decrease in the functional class of CHF by 1 point

    Time frame: Every 12 months, up to 3 years

  2. The proportion of subjects hospitalized for decompensated CHF in the departments of therapeutic and cardiology profiles *

    Time frame: Every 12 months, up to 3 years

  3. Proportion of subjects with newly diagnosed type 2 diabetes*

    Time frame: Every 12 months

  4. Proportion of subjects with deterioration of renal function*

    Time frame: Every 12 months, up to 3 years

  5. Proportion of subjects with newly diagnosed malignant neoplasm*

    Time frame: Every 12 months, up to 3 years

  6. Proportion of subjects who died from CV causes*

    Time frame: Every 12 months, up to 3 years

  7. Proportion of subjects with different causes of death*

    Time frame: Every 12 months, up to 3 years

  8. Incidence and event rates (per 100 subject-years) for hospitalizations due to HF*

    Time frame: Every 12 months, up to 3 years

  9. Incidence and event rates (per 100 subject-years) for death from CV causes*

    Time frame: Every 12 months, up to 3 years

  10. Incidence and event rates (per 100 subject-years) for death from any cause*

    Time frame: Every 12 months, up to 3 years

  11. The proportion of subjects with preferential drug provision for cardiovascular disease, diabetes mellitus*

    Time frame: Every 12 months, up to 3 years

  12. Average frequency of outpatient visits of subjects with CHF to medical institutions*

    Time frame: Every 12 months, up to 3 years

  13. The proportion of subjects registered with a cardiologist or therapist with different phenotypes and stages of CHF*

    Time frame: Every 12 months, up to 3 years

  14. Average frequency of telephone patronage *

    \*- in the overall sample and in groups of subjects with HFrEF, HFmrEF, HFpEF and in different age categories (18-49 years; 50-64 years; 65-74 years; 75-85 years;\>85 years); of working/non-working age; employed/non-employed

    Time frame: Every 12 months, up to 3 years

07

Study locations

1 of 1 sites recruiting
  • National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Organization
    Moscow, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2027, 38 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 38 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 12, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06683001
Lead sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
Oct 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Olga N Svirida, MD, PhD
Contact
ONSvirida@Cardio.ru
+74954146552
Vadim Yu Kuznetsov, PhD
Contact
vykuznetsov@cardio.ru
+74954146249
Sergey A Boytsov, Prof.
study chair · E.I.Chazov Cardiology Center
Zoya N Blankova, MD, PhD
study director · E.I.Chazov Cardiology Center
Fail' T Ageev, Prof.
principal investigator · E.I.Chazov Cardiology Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion